Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

81.52EUR
21 Jul 2017
Change (% chg)

€-1.25 (-1.51%)
Prev Close
€82.77
Open
€82.75
Day's High
€83.30
Day's Low
€81.28
Volume
2,988,091
Avg. Vol
2,428,759
52-wk High
€92.97
52-wk Low
€66.72

SASY.PA

Chart for SASY.PA

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including... (more)

Overall

Beta: 0.90
Market Cap(Mil.): €102,776.70
Shares Outstanding(Mil.): 1,260.75
Dividend: 2.96
Yield (%): 3.63

Financials

  SASY.PA Industry Sector
P/E (TTM): 22.45 11.79 15.85
EPS (TTM): 3.63 -- --
ROI: -- -10.04 -8.31
ROE: -- -9.89 -7.95

EU follows U.S. in backing Sanofi, Regeneron eczema drug

LONDON, July 21 The European Medicines Agency on Friday recommended approval of Regeneron Pharmaceuticals and Sanofi's new drug Dupixent for atopic dermatitis, a product many analysts see as the most important growth driver for the two companies.

Jul 21 2017

FDA tentatively approves Merck's copycat of Sanofi's Lantus

Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its biosimilar version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus.

Jul 20 2017

FDA tentatively approves Merck's copycat of Sanofi's Lantus

Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its biosimilar version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus.

Jul 20 2017

FDA tentatively approves Merck's copycat of Sanofi's Lantus

July 20 Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its biosimilar version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus.

Jul 20 2017

Ablynx signs Sanofi deal potentially worth up to $2.8 billion

French drugmaker Sanofi boosted its early-stage pipeline in immunology on Thursday by signing a deal with Ablynx that could earn the Belgian biotech firm as much as 2.4 billion euros ($2.8 billion).

Jul 20 2017

Ablynx signs Sanofi deal potentially worth up to $2.8 bln

July 20 French drugmaker Sanofi boosted its early-stage pipeline in immunology on Thursday by signing a deal with Ablynx that could earn the Belgian biotech firm as much as 2.4 billion euros ($2.8 billion).

Jul 20 2017

BRIEF-Havas CEO says company likely to keep Sanofi budget

* Havas CEO Yannick Bollore told reporters during a media lunch that he felt Havas was likely to keep the advertising budget for drugmaker Sanofi.

Jul 18 2017

BRIEF-Emergent Biosolutions updates terms of termination of agreement related to acquisition of Sanofi's acam2000 business

* Emergent Biosolutions updates on terms of any termination of agreement related to acquisition of acam2000 business from Sanofi

Jul 14 2017

BRIEF-Emergent BioSolutions to acquire ACAM2000 business from Sanofi

* Emergent biosolutions to acquire acam2000® business from sanofi

Jul 14 2017

Sanofi lawsuit over Novo Nordisk diabetes drug marketing narrowed

A New Jersey federal judge has narrowed a lawsuit filed by Sanofi SA accusing Novo Nordisk of falsely claiming that Sanofi's insulin drugs would no longer be available to many U.S. patients so that it could promote its competing drug.

Jul 11 2017

Earnings vs. Estimates